New brand-name drugs typically grab the life science headlines. A venture capital firm will invest tens of millions to develop one and a pharmaceutical company hopes to recoup hundreds of millions by selling it. But a shortage of one particular chemotherapy... Read more »
Even as researchers discover more links between specific proteins and human disease, it’s still hard to find small molecules or antibodies that can bind to those drug targets.
San Diego biotech Plexium is the latest addition to the growing number of... Read more »
Atomico, a European venture capital firm, has helped persuade Cambridge, UK-based Healx to return to the capital market a year earlier than anticipated. The biotech has just raised $56 million in Series B funding to bankroll its mission to use AI... Read more »
Nuance Communications’ plan to lighten the clerical burden on physicians is coming into focus, and it involves an assist from tech giant Microsoft.
Nuance (NASDAQ: NUAN), the 27-year-old speech recognition technology pioneer, in February revealed it’s developing a device that... Read more »
Cell therapies are made by tinkering with a patient’s immune cells so that they can better recognize and destroy cancer cells. These drugs give patients another treatment option for certain cancers that haven’t responded to anything else. ArsenalBio CEO Ken Drazan... Read more »
An experimental drug that was the centerpiece of a $1.6 billion Eli Lilly acquisition last year has now failed a pivotal test in pancreatic cancer.
Eli Lilly (NYSE: LLY) said Wednesday that patients treated with its drug candidate pegilodecakin, plus... Read more »
Alexion Pharmaceuticals is acquiring Achillion Pharmaceuticals for $930 million, a deal that could strengthen its position providing treatments for a rare blood disorder.
According to financial terms announced Wednesday, Boston-based Alexion (NASDAQ: ALXN) will pay $6.30 per share of Achillion... Read more »
Glenmark Pharmaceuticals, which has made generic drugs for about four decades, on Tuesday formally spun off its drug R&D unit as an independent business aiming to advance a handful of novel molecules the Indian company has developed in recent years.
The... Read more »
Cyteir Therapeutics has $40.2 million more in cash to support early-stage tests of a drug intended to treat cancer by targeting a tumor repair mechanism.
The new cash that Cyteir announced Tuesday adds to a Series B round of funding it... Read more »
Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms.
The FDA approved the drug, lasmiditan... Read more »
Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs.
The San Francisco firm offered 7.1 million shares priced at $20 each, which was the low end of the $20 to $22... Read more »
Congrats to this year’s Nobel Prize winners in medicine… although, we have to ask: For the US researchers who are honored, isn’t there something crushing about a call in the middle of the night from Sweden, interrupting a dream about... Read more »
Ra Pharmaceuticals, whose lead autoimmune disease drug candidate is viewed as a potential alternative to one of the most expensive medicines in the world, is being acquired by Belgian pharmaceuticals giant UCB in a $2.1 billion deal.
According to terms announced... Read more »